Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4/6) inhibitor and an mTOR inhibitor for treating cancer

Details for Australian Patent Application No. 2011240735 (hide)

Owner Novartis AG

Inventors Borland, Maria; Brain, Christopher Thomas; Doshi, Shivang; Kim, Sunkyu; Ma, Jianguo; Murtie, Josh; Zhang, Hong

Agent Davies Collison Cave

Pub. Number AU-A-2011240735

PCT Pub. Number WO2011/130232

Priority 61/323,541 13.04.10 US

Filing date 12 April 2011

Wipo publication date 20 October 2011

International Classifications

A61K 31/436

A61K 31/519 - ortho- or peri-condensed with heterocyclic rings

A61K 45/06 Medicinal preparations containing active ingredients not provided for in groups

A61P 35/00 Antineoplastic agents

Event Publications

1 November 2012 PCT application entered the National Phase

  PCT publication WO2011/130232 Priority application(s): WO2011/130232

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011240738-Rich browser-based word processor

2011240695-Real-time collaboration in a hosted word processor